PTC Therapeutics' stock soared 13.49% during the intraday trading session on Friday, reflecting a surge in investor confidence driven by the company's latest financial performance and positive analyst sentiment.

The significant price movement follows the biopharmaceutical company's report of first-quarter 2026 revenue of $273 million, which substantially exceeded analyst consensus estimates. The company also posted an adjusted loss per share of $0.03, a marked improvement over the expected loss, and raised its full-year 2026 revenue guidance to a range above previous forecasts and consensus.

Investor optimism was further amplified by a series of analyst actions, including TD Cowen upgrading the stock to Buy from Hold and raising its price target, Wells Fargo increasing its target price, and Morgan Stanley reiterating its Buy rating. The collective bullish stance from multiple financial institutions underscores the positive outlook for PTC Therapeutics following its strong quarterly results and promising guidance.